Kidney cancer drug study halted after just 6 patients
NCT ID NCT03846128
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to see if the amount of sunitinib in the blood affects side effects and how well the drug works in people with metastatic kidney cancer. Researchers planned to collect extra blood samples during routine visits from patients starting sunitinib as their first treatment. However, the study was terminated early after enrolling only 6 participants, so the findings are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sunitinib
- What this could lead to
- If successful, this could help doctors personalize sunitinib dosing to reduce severe side effects while maintaining effectiveness.
- What could go wrong
- The study was terminated early with only 6 participants, so results are very limited and may not apply broadly. No new treatment was tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de ROUEN
Rouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a personal coach at home boost energy for cancer patients?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Radiation boosts immunotherapy in kidney cancer trial
- Immunotherapy duo shows promise in kidney cancer battle
- Brain cancer trial halted early: can Memory-Sparing radiation help when tumors return?